Keisuke Shigeta

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer

Keisuke Shigeta, Masanori Hasegawa, Takako Hishiki et al. · The EMBO Journal · 2023 · 81 citations · Full text

Medicine, Molecular Biology, Oncology +15

High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy

Keisuke Shigeta, Takeo Kosaka, Shigehisa Kitano et al. · Annals of Surgical Oncology · 2016 · 58 citations

Medicine, Oncology, Pharmacology +12

The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients

Koichiro Ogihara, Eiji Kikuchi, Keisuke Shigeta et al. · Urologic Oncology Seminars and Original Investigations · 2020 · 56 citations

Medicine, Oncology, Pharmacology +16

Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions

Yuki Arita, Keisuke Shigeta, Hirotaka Akita et al. · European Radiology · 2020 · 44 citations · Full text

Medicine, Radiology, Urology +17

The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma

Keisuke Shigeta, Eiji Kikuchi, Masayuki Hagiwara et al. · The Journal of Urology · 2017 · 41 citations

Medicine, Surgery, Urology +17